DNMT3B and cancer: Nevertheless, the regulatory mechanism responsible for the role of DNMT3B in cancer malignancies remains largely unknown, and its diagnostic or prognostic effectiveness reflected in a large proportion of the registered clinical trials remains still suboptimal, suggesting that the mechanisms underlying de novo DNA methylation and the clinical significance of DNA methylation need to be further investigated and better understood.